Michele F Eisenga1, Dorien M Zelle2, John H Sloan3, Carlo A J M Gaillard2, Stephan J L Bakker2, Robin P F Dullaart2. 1. Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands m.f.eisenga@umcg.nl. 2. Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 3. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN.
Abstract
OBJECTIVE: New-onset diabetes after transplantation (NODAT) is a major complication in renal transplant recipients (RTRs). Cholesterol metabolism has been linked to diabetes development. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is crucial in LDL receptor regulation. Its association with NODAT is unknown. We prospectively determined the association between serum PCSK9 levels and NODAT development and then with all-cause mortality, cardiovascular mortality, and renal graft failure. RESEARCH DESIGN AND METHODS: In a university setting, nondiabetic RTRs recruited between 2001 and 2003 with a functional graft for ≥1 year were eligible. Serum PCSK9 was measured by ELISA. Cox proportional hazards analysis was used to assess the association of PCSK9 with the development of NODAT, all-cause mortality, cardiovascular mortality, and graft failure. RESULTS: In 453 RTRs (age 51 ± 12 years, 56% male; 6.1 [2.7-11.7] years after transplantation), serum PCSK9 was 107.1 ± 43.4 μg/L. During a median follow-up of 10 years, 70 RTRs developed NODAT, 123 died, and 59 developed graft failure. NODAT occurred more frequently in the upper PCSK9 tertile (23%) versus the lowest two PCSK9 tertiles (12%; P < 0.001). In crude Cox regression analyses, PCSK9 was significantly associated with development of NODAT (hazard ratio 1.34 [95% CI 1.10-1.63]) per SD change (P = 0.004). This association remained independent of adjustment for potential confounders, including statin use. PCSK9 was not associated with all-cause mortality, cardiovascular mortality, or graft failure. CONCLUSIONS: Circulating PCSK9 is associated with NODAT in RTRs. The PCSK9 pathway may contribute to the pathogenesis of NODAT.
OBJECTIVE: New-onset diabetes after transplantation (NODAT) is a major complication in renal transplant recipients (RTRs). Cholesterol metabolism has been linked to diabetes development. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is crucial in LDL receptor regulation. Its association with NODAT is unknown. We prospectively determined the association between serum PCSK9 levels and NODAT development and then with all-cause mortality, cardiovascular mortality, and renal graft failure. RESEARCH DESIGN AND METHODS: In a university setting, nondiabetic RTRs recruited between 2001 and 2003 with a functional graft for ≥1 year were eligible. Serum PCSK9 was measured by ELISA. Cox proportional hazards analysis was used to assess the association of PCSK9 with the development of NODAT, all-cause mortality, cardiovascular mortality, and graft failure. RESULTS: In 453 RTRs (age 51 ± 12 years, 56% male; 6.1 [2.7-11.7] years after transplantation), serum PCSK9 was 107.1 ± 43.4 μg/L. During a median follow-up of 10 years, 70 RTRs developed NODAT, 123 died, and 59 developed graft failure. NODAT occurred more frequently in the upper PCSK9 tertile (23%) versus the lowest two PCSK9 tertiles (12%; P < 0.001). In crude Cox regression analyses, PCSK9 was significantly associated with development of NODAT (hazard ratio 1.34 [95% CI 1.10-1.63]) per SD change (P = 0.004). This association remained independent of adjustment for potential confounders, including statin use. PCSK9 was not associated with all-cause mortality, cardiovascular mortality, or graft failure. CONCLUSIONS: Circulating PCSK9 is associated with NODAT in RTRs. The PCSK9 pathway may contribute to the pathogenesis of NODAT.
Authors: Rubab F Malik; Yaqi Jia; Sherry G Mansour; Peter P Reese; Isaac E Hall; Sami Alasfar; Mona D Doshi; Enver Akalin; Jonathan S Bromberg; Meera N Harhay; Sumit Mohan; Thangamani Muthukumar; Bernd Schröppel; Pooja Singh; Francis L Weng; Heather R Thiessen Philbrook; Chirag R Parikh Journal: Kidney360 Date: 2021-06-02
Authors: Pragyi Shrestha; Saritha Adepu; Romain R Vivès; Rana El Masri; Astrid Klooster; Fleur Kaptein; Wendy Dam; Stephan J L Bakker; Harry van Goor; Bart van de Sluis; Jacob van den Born Journal: J Am Soc Nephrol Date: 2021-03-23 Impact factor: 14.978
Authors: Sara Sokooti; Frank Klont; Sok Cin Tye; Daan Kremer; Rianne M Douwes; Gérard Hopfgartner; Robin P F Dullaart; Hiddo J L Heerspink; Stephan J L Bakker Journal: Nephrol Dial Transplant Date: 2022-06-23 Impact factor: 7.186
Authors: Meenu Rohini Rajan; Matus Sotak; Fredrik Barrenäs; Tong Shen; Kamil Borkowski; Nicholas J Ashton; Christina Biörserud; Tomas L Lindahl; Sofia Ramström; Michael Schöll; Per Lindahl; Oliver Fiehn; John W Newman; Rosie Perkins; Ville Wallenius; Stephan Lange; Emma Börgeson Journal: Sci Rep Date: 2019-10-28 Impact factor: 4.379